Speaker: Jean Viallet, CEO & Scientific Director at INOVOTION

Topic: A unique platform for in vivo, 3Rs-compliant evaluation of oncology & immuno-oncology drug candidates

Inovotion has built a xenograft model using immunocompetent chicken embryos with intrinsic benefits: 3rs, fast, robust, affordable, predictive, and time saving.

The model provides:

• Cancer model development from patient biopsies
• Target validation & multi-cancer screening
• Support for drug delivery systems and cell therapies

During the session, Jean Viallet shared real case studies demonstrating how this technology can accelerate drug discovery, reduce costs, and deliver a clear competitive edge.